VIVITROL Drug Patent Profile

Which patents cover Vivitrol, and when can generic versions of Vivitrol launch?

Vivitrol is a drug marketed by Alkermes and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has eighteen patent family members in eleven countries.

The generic ingredient in VIVITROL is naltrexone. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the naltrexone profile page.

DrugPatentWatch^® Generic Entry Outlook for Vivitrol

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 15, 2029. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (naltrexone), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for VIVITROL

International Patents:	18
US Patents:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIVITROL

Paragraph IV (Patent) Challenges for VIVITROL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIVITROL	Extended-release Injectable Suspension	naltrexone	380 mg/vial	021897	1	2020-06-18

US Patents and Regulatory Information for VIVITROL

VIVITROL is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkermes	VIVITROL	naltrexone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	021897-001	Apr 13, 2006		RX	Yes	Yes

International Patents for VIVITROL

See the table below for patents covering VIVITROL around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	522335	Preparation of injectable suspensions having improved injectability
Poland	329720
Brazil	0111060
Australia	733199
Norway	20065995

Supplementary Protection Certificates for VIVITROL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2316456	132017000142109	Italy		PRODUCT NAME: NALTREXONE/BUPROPIONE(MYSIMBA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/988, 20150330
2316456	2017/059	Ireland		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150326
2316456	2017C/064	Belgium		PRODUCT NAME: NALTREXONE/BUPROPION; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330
2316456	1790064-8	Sweden		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330
2316456	SPC/GB17/078	United Kingdom		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE.; REGISTERED: UK EU/1/14/988 20150330; UK PLGB 50742/0001 20150330

VIVITROL (naltrexone ER for alcohol and opioid dependence): Investment scenario and fundamentals analysis

Last updated: April 25, 2026

What is VIVITROL and what markets does it serve?

VIVITROL is an extended-release (ER) injectable formulation of naltrexone indicated for:

• Alcohol dependence (helping prevent relapse after detoxification)
• Opioid dependence (as part of relapse prevention, after opioid detoxification)

The product is administered once monthly via intramuscular injection (site-specific for gluteal dosing), making it a pharmacy/medical benefit hybrid where persistence and adherence drive usage.

How does VIVITROL fit into payer and prescriber economics?

VIVITROL’s value proposition is behavioral relapse prevention with:

• A depot delivery profile that reduces missed-dose risk versus oral naltrexone
• Clinical workflows that rely on sustained follow-up for monthly injection visits

From an investment standpoint, the fundamentals hinge on:

1. Volume durability: persistence of patients on monthly therapy
2. Channel mix: buy-and-bill practices, insurance authorization friction, and specialty pharmacy routing
3. Net price trajectory: rebates, contracting dynamics, and competitive substitutes

Who controls VIVITROL’s commercial performance?

The manufacturer and commercialization rights determine pricing power, contracting discipline, and resource allocation against competing opioid use disorder (OUD) and alcohol use disorder (AUD) modalities.

VIVITROL’s competitive set typically includes:

• Other AUD medications (e.g., acamprosate, disulfiram, and newer pipelines depending on region)
• OUD medications (notably opioid agonist therapies like buprenorphine and methadone; and opioid antagonist strategy)
• Behavioral programs and care models that can shift prescribing patterns across time

What is the investment scenario for VIVITROL?

Base case

• VIVITROL maintains a stable share in segments that prefer or require opioid antagonist strategy and monthly supervised dosing.
• Growth is driven by incremental patient starts, continuation/persistence, and contracting stability rather than step-change adoption.

Upside case

• Net price holds up better than peers due to payer preference for depot adherence in high nonadherence cohorts.
• Prescriber confidence rises through expanded site-of-care infrastructure and tighter follow-up protocols.
• Revenue benefits from improved persistence (longer time-on-treatment per patient).

Downside case

• Substitution risk increases as alternative AUD/OUD therapies, care models, and adherence tools reduce reliance on monthly naltrexone depot.
• Net price pressure intensifies due to formulary tightening, higher rebate pressure, or increased payer restriction.
• Higher discontinuation rates reduce utilization per patient.

What are the key fundamentals that determine revenue trajectory?

1) Demand drivers

• Diagnosis incidence for AUD and OUD relapse prevention use cases
• Conversion from screening to treatment initiation
• Treatment persistence and missed-dose rates (depot vs oral)

2) Supply and continuity

• Sustained manufacturing capacity for long-term depot supply
• Stability of packaging and cold-chain or handling requirements (if applicable for site administration)

3) Competitive substitution

• Relative positioning versus opioid agonist maintenance models for OUD
• Position versus oral AUD options where payer prefers lower administrative friction

4) Payer and access

• Prior authorization and step therapy practices
• Contracting outcomes that shape net price

How does VIVITROL’s clinical profile translate into adoption?

VIVITROL’s clinical adoption typically depends on:

• Confirmed opioid detoxification status before initiation in OUD relapse prevention settings
• Ability to adhere to monthly injection visits
• Patient suitability based on contraindications and risk tolerance

These translate into an adoption curve where uptake is strongest in care settings with established follow-up infrastructure (addiction medicine clinics, integrated behavioral health programs, and hospital-based substance use units).

What does the label require that matters to business operations?

Operationally, label requirements that influence utilization include:

• Detoxification timing before initiation in opioid-related indications
• Ongoing counseling and monitoring aligned with relapse prevention frameworks
• Safety constraints that can reduce patient pool eligibility and increase discontinuation risk

Revenue sensitivity: where management levers usually sit

Commercial levers

• Contracting discipline to protect net price
• Channel management to maintain reliable access pathways
• Patient support services that reduce missed injections

Medical affairs levers

• Evidence dissemination focused on relapse prevention outcomes and depot adherence benefits
• Provider education on initiation protocols and patient selection

Pipeline and lifecycle levers

• Line extensions and next-gen depot formulations (if any in the platform)
• Label expansions or new indications, if supported by clinical work
• Risk mitigation for competitive encroachment via sequencing strategies in care pathways

Competitive landscape: what investors should watch

OUD care pathway shift

OUD treatment often emphasizes medication-assisted treatment modalities. Antagonist-based relapse prevention can face share pressure if payers and clinicians default to agonist maintenance for broader eligibility, dosing convenience, or continuity.

AUD modality preferences

AUD care is more fragmented across medications and behavioral therapies. Depot naltrexone competes on adherence and relapse prevention efficacy in appropriate patient subsets. Net sales performance depends on whether those subsets remain payer-favored.

Depot platform competition

Within long-acting injectable (LAI) addiction treatment, any incremental head-to-head adoption gains or guideline shifts can swing share.

Key investment metrics to track for VIVITROL

The most predictive performance indicators for a monthly depot are:

• TRx or shipments trending (if available) and growth vs prior periods
• Discontinuation rate proxies via prescription duration and refill cadence
• Net price indicators such as ASP trends relative to list price (and any public rebate disclosures)
• Account access: formulary tier placement changes and policy updates
• Utilization: injection volume per active patient (inferred from reported sales and known dosing)

Regulatory and safety watchpoints

VIVITROL is subject to routine pharmacovigilance. Investors should monitor:

• FDA safety communications affecting depot naltrexone use
• Label changes that broaden or restrict patient eligibility
• Post-marketing findings that influence prescriber confidence

What is the bear thesis to stress-test?

A disciplined downside case for VIVITROL usually assumes:

• Net price erosion from formulary renegotiation
• Competitive substitution from other AUD/OUD standards of care
• Persistence deterioration as patient management shifts toward models that reduce injection-based adherence

The key is that monthly administration makes VIVITROL less resilient than oral therapies in environments where access to clinic visits is constrained.

What is the bull thesis to stress-test?

A disciplined upside case assumes:

• Improved persistence through clinic workflows, patient support, and adherence programs
• Payer preference for supervised depot dosing in populations with high relapse risk
• Contracting outcomes that sustain net price even if gross demand growth is modest

Depot products can outperform in a base-demand market when retention and net price are protected.

How to map VIVITROL fundamentals to an investment stance

If you are targeting stability

VIVITROL typically fits a “defensive growth within a mature category” view where:

• Growth is incremental
• Variance is driven by persistence and net pricing rather than sudden adoption spikes

If you are targeting upside

VIVITROL fits an upside view when:

• Formulary position strengthens
• Competing therapies face access or adherence constraints that shift patients to depot strategies
• Medical programs improve initiation-to-maintenance conversion

Key Takeaways

• VIVITROL is an ER injectable depot formulation of naltrexone used for AUD relapse prevention and OUD relapse prevention after detoxification, requiring sustained monthly injection follow-up.
• Fundamentals depend on persistence, payer access, and net price, not just patient starts.
• Investment outcomes are most sensitive to formulary and contracting dynamics and to shifts in AUD/OUD care pathways that determine whether antagonist-based relapse prevention maintains share.
• The bear case centers on net price erosion and substitution toward alternative AUD/OUD standards; the bull case centers on improved retention and payer preference for depot adherence.

FAQs

1) What makes VIVITROL commercially different from oral naltrexone?
Its extended-release depot dosing reduces missed doses but increases reliance on monthly injection access and follow-up.

2) What drives VIVITROL revenue most directly?
Active patient persistence and ongoing injection utilization, plus net price after rebates and contracting.

3) How does payer policy typically influence VIVITROL performance?
Formulary tiering, prior authorization, and step edits determine access and can materially shift net price.

4) What are the main competitive threats to VIVITROL?
Substitution within AUD pharmacotherapy choices and OUD maintenance pathways, especially approaches that do not require monthly injections.

5) What operational factor matters most for the monthly depot model?
Continuity of clinic-administered dosing schedules and patient adherence to monthly visits.

---

References

[1] U.S. Food and Drug Administration. VIVITROL (naltrexone for extended-release injectable suspension) prescribing information. FDA label.
[2] FDA. Drug Trials Snapshots: Vivitrol. FDA.
[3] PubChem. Naltrexone (CAS). National Library of Medicine.